Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 19 citing articles:

Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions
Rajesh Kumar Jha, Sara Lopez-Trevino, Haritha R. Kankanamalage, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1098-1098
Open Access | Times Cited: 19
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 5
Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Jingxing Li, Tzu-Ju Hsu, Heng-Jun Lin, et al.
JAMA Network Open (2025) Vol. 8, Iss. 3, pp. e252577-e252577
Open Access | Times Cited: 1
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Walter Masson, Martín Lobo, Juan Patricio Nogueira, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Leandro Fadel, Gigi Thao, Tanvi Chitre, et al.
Cureus (2025)
Open Access
Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing
Christof Wedemeyer, Martin Peters, Graham L. Jones
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
Nancy Haff, Daniel M. Horn, Gauri Bhatkhande, et al.
American Heart Journal (2025)
Closed Access
Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Asma Mousavi, Shayan Shojaei, Hamidreza Soleimani, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation
Mislav Radić, Andrej Belančić, Hana Đogaš, et al.
Metabolites (2025) Vol. 15, Iss. 3, pp. 206-206
Open Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
Novel Metabolites Associated With Blood Pressure After Dietary Interventions
Yixi Sun, Ruiyuan Zhang, Ling Tian, et al.
Hypertension (2024) Vol. 81, Iss. 9, pp. 1966-1975
Closed Access | Times Cited: 2
Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial
YongSheng Cao, Shujie Cao, Jiangang Zhao, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Glucagon-like peptide-1 agonists in cardiovascular diseases, a bibliometric analysis from inception to 2023
Abinash Mahapatro, Ali Bozorgi, Sri Usha Jeevani Obulareddy, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 11, pp. 6602-6618
Open Access | Times Cited: 1
Impact of Vitamin E Supplementation on High‐Density Lipoprotein in Patients With Haptoglobin Genotype–Stratified Diabetes: A Systematic Review of Randomized Controlled Trials
Panpan Zheng, Liwen Zhang, Dan Sheng, et al.
Journal of Diabetes Research (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
GLP-1 Agonists for Weight Loss and Beyond
Connor Quinter, Hanh Motilall, Kelley Maberry
Transformative Medicine (2024) Vol. 3, Iss. 4, pp. 143-146
Closed Access | Times Cited: 1
Microvascular vasoregulatory dysfunction in African Americans - An enhanced opportunity for early prevention and treatment of atherosclerotic cardiovascular disease
Renée P. Bullock-Palmer, Panithaya Chareonthaitawee, Ervin R. Fox, et al.
American Heart Journal Plus Cardiology Research and Practice (2024) Vol. 40, pp. 100382-100382
Open Access
Classification, Symptoms, Treatment and Preventive Strategies of Diabetes. A guide to the basic
Magda Madoń, Patrycja Proszowska, Daria Sieniawska, et al.
Journal of Education Health and Sport (2024) Vol. 70, pp. 50192-50192
Open Access
Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review
Chithra Sreenivasan, Aneri Parikh, Aida J Francis, et al.
Cureus (2024)
Open Access
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
Davide Misceo, Gabriele Mocciaro, Simona D’Amore, et al.
Nutrition & Metabolism (2024) Vol. 21, Iss. 1
Open Access
Page 1

Scroll to top